SCIENTIFIC PROGRAMME

Sunday 23 October

IW1	10.30–11.30	**Industry Workshop**	**Carron Room**
	11.30–12.00	Break	
WS1	12.00–13.30	**Case Study Session**	**Clyde Auditorium**
		In collaboration with the University of Liverpool Drug Interactions website: **www.hiv-druginteractions.org**	
WS1CH WS1CH		Co-Chairs: *Saye Khoo, University of Liverpool, Liverpool, UK* *Jonathan Schapiro, National Hemophilia Center, Tel Aviv, Israel*	
WS1CH	12.00–12.10	**Welcome and update on DDI websites** *Saye Khoo*	
WS11	12.10–12.35	**Long-acting ARVs for PrEP** *Ian McGowan, University of Pittsburgh, Pittsburgh, USA*	
WS12	12.35–13.00	**Case 1: managing multiple co-morbidities** Presenter: *Sally Jewsbury, Central Manchester NHS Foundation Trust, Manchester, UK* Discussant: *Marta Boffito, St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK*	
WS13	13.00–13.25	**Case 2: more than just ARVs and chemotherapy** Presenter: *Alessia Dalla Pria, Chelsea and Westminster Hospital, London, UK* Discussant: *Fiona Marra, Gartnavel Hospital, Glasgow, UK*	
WS1CH	13.25–13.30	**Closing remarks** *Saye Khoo*	
	13.30–14.30	**Lunch**	**Congress Exhibition Hall (Hall 4)**
SS1	14.30–16.00	**Industry Symposium**	**Clyde Auditorium**
	16.00–16.30	**Coffee**	**Congress Exhibition Hall (Hall 4)**
	16.30–16.45	**Official Opening**	**Clyde Auditorium**
		Andrew Phillips, University College London, UK Welcome from Glasgow City *Bailie Marie Garrity, Glasgow City Council, Glasgow, UK*	
	16.45–17.30	**Joep Lange and Jacqueline van Tongeren Memorial Lecture**	**Clyde Auditorium**
		Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS	
	16.45–16.55	**Introduction** *Catherine Hankins, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, The Netherlands*	

KL1	16.55–17.30	**Ending the HIV/AIDS pandemic: follow the science** *Anthony S Fauci, National Institute of Allergy and Infectious Diseases (NIAID)/ National Institutes of Health (NIH), Bethesda, USA*
KL	17.30–18.30	**Keynote Lectures** — **Clyde Auditorium**
KLCH KLCH		Co-Chairs: *Catherine Hankins* *Andrew Phillips*
KL2	17.30–18.00	**Treatment for cancer, HIV and viral hepatitis in Europe using low cost generic drugs: what could be done?** *Andrew Hill, St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK*
KL3	18.00–18.30	**Revolution in prevention in low and middle income settings** *Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa, and President, International AIDS Society (IAS)*
	18.30–19.30	**Welcome Reception** — **Congress Exhibition Hall (Hall 4)**

Monday 24 October

O11	08.45–10.45	**Antiretrovirals: Progress and Remaining Challenges** — **Clyde Auditorium**
O11CH O11CH		Co-Chairs: *Kevin M de Cock, Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Nairobi, Kenya* *Cristina Mussini, University of Modena and Reggio Emilia, Infectious Disease Clinic, Modena, Italy*
	08.45–09.30	**Lock Lecture** — **Clyde Auditorium**
		HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme
	08.45–08.50	**Lock Lecture: introduction** *David Galloway, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK*
O111	08.50–09.30	**Lock Lecture: HIV treatment as prevention: from a research hypothesis to a new global target and beyond** *Julio Montaner, British Columbia Centre for Excellence in HIV/AIDS, and University of British Columbia, Vancouver, Canada*
O112	09.30–09.50	**Initiation of ART early in HIV infection: START to finish** *Jens D Lundgren, CHIP and PERSIMUNE, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*
O113	09.50–10.10	**Transition to adult care** *Pablo Rojo, Paediatric Infectious Diseases, Hospital 12 de Octubre, Complutense University, Madrid, Spain*

SCIENTIFIC PROGRAMME (continued)

O114*	10.10–10.25	**Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe** *Kamilla Grønborg Laut, CHIP, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*	
	10.25–10.45	**Panel discussion**	
	10.45–11.15	**Coffee**	**Congress Exhibition Hall (Hall 4)**
O12	11.15–12.30	**Treatment Strategies**	**Clyde Auditorium**
O12CH O12CH		Co-Chairs: *Christine Katlama, Pitié-Salpêtrière Hospital, Paris, France* *Daniel R Kuritzkes, Brigham and Women's Hospital, Harvard Medical School, Boston, USA*	
O121*	11.15–11.30	**Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial** *Roberta Gagliardini, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy*	
O122*	11.30–11.45	**Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial** *Laura Ciaffi, UMI 233, IRD INSERM, Montpellier, France*	
O123*	11.45–12.00	**Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)** *Christian Callebaut, Clinical Virology, Gilead Sciences, Foster City, USA (Industry Speaker†)*	
O124*	12.00–12.15	**Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks** *Chloe Orkin, Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK*	
O125*	12.15–12.30	**Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults** *Francois Raffi, Infectious and Tropical Diseases, CHU de Nantes, Nantes, France*	
	12.30–14.00	**Scientific Posters and Lunch**	**Congress Exhibition Hall (Hall 4)**
	12.45–13.45	**Antiretroviral Therapy: Efficacy and Adverse Events: Poster Discussion Session**	**Clyde Auditorium**
PCH PCH		Co-Chairs: *Mark Wainberg, McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Canada* *Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda*	

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.

P021	12.45–12.55	**Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort** *Antonella d'Arminio Monforte, Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy*
P035	12.55–13.05	**Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): subgroup analyses** *Margaret Johnson, Centre for HIV Medicine, Royal Free Hospital, London, UK*
P210	13.05–13.15	**Psychiatric adverse events from the DTG ART-naïve phase 3 clinical trials** *Romina Quercia, Research and Development, ViiV Healthcare, Brentford, UK (Industry Speaker†)*
P209	13.15–13.25	**Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity** *Nicole Pagani, St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK*
P208	13.25–13.35	**Tryptophan metabolism and its relationship with central nervous system toxicity in subjects switching from efavirenz to dolutegravir** *Michael Keegan, HIV Research Unit, Clinical Trials Centre, Imperial College London, and ViiV Healthcare Ltd, London, UK (Industry Speaker†)*
P352	13.35–13.45	**High rates of multi-class drug resistance in HIV-1-infected individuals monitored with CD4 cell count in Uganda** *Amrei von Braun, College of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala, Uganda*
	12.45–13.45	**Ageing and Cancer: Poster Discussion Session** — **Lomond Auditorium**
PCH		Co-Chairs: *Caroline Sabin, Department of Infection and Population Health, University College London, London, UK*
PCH		*Andrew Winter, NHS Greater Glasgow and Clyde, Glasgow, UK*
P154	12.45–12.55	**Ageing and the evolution of co-morbidities among HIV patients in the EuroSIDA cohort** *Sara Lopes, Health Economics and Outcomes Research, Gilead Sciences, London, UK (Industry Speaker†)*
P189	12.55–13.05	**The extent of B-cell activation and dysfunction preceding lymphoma development** *Alvaro Borges, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark*
P155	13.05–13.15	**Future challenges for clinical care of an ageing population infected with HIV: a 'geriatric HIV' modelling study** *Davide De Francesco, Department of Infection and Population Health, University College London, London, UK*

†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.

P156	13.15–13.25	**Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study** *Mikaela Smit, Department of Infectious Disease Epidemiology, Imperial College London, London, UK*
P153	13.25–13.35	**Health-related costs in chronic HIV infection: a case-control study versus general population using a claims-based approach in Germany** *Eva Wolf, Clinical Research, MUC Research, Munich, Germany*
P190	13.35–13.45	**Survival in HIV-1-infected individuals with diagnosis of lymphoma compared to general population: data from ICONA Foundation cohort** *Antonella Cingolani, Infectious Diseases, Catholic University, Rome, Italy*
CS1	14.00–15.30	**Challenging Cases in HIV: Interactive Case Study Session** — **Clyde Auditorium**
		In collaboration with the International Antiviral Society-USA (IAS-USA)
CS1CH CS1CH		Co-Chairs: *Pedro Cahn, Fundacion Huesped, Juan A Fernandez Hospital, Buenos Aires, Argentina* *Peter Reiss, Academic Medical Center, University of Amsterdam and HIV Monitoring Foundation, Amsterdam, The Netherlands*
CS11	14.00–14.30	**Case 1: antiretroviral therapy (ART) strategies: choosing an initial regimen** *Roy M Gulick, Weill Cornell Medicine, New York, USA*
CS12	14.30–15.00	**Case 2: management of HIV infection in the heavily treatment-experienced patient** *Ian Williams, Department of Infection and Population Health, University College London, London, UK*
CS13	15.00–15.30	**Case 3: implementation and issues in pre-exposure prophylaxis (PrEP)** *Jean-michel Molina, Saint-Louis Hospital and University of Paris, Paris, France*
CS13PL		Panel: *Pedro Cahn* *Roy M Gulick* *Jean-michel Molina* *Peter Reiss* *Ian Williams*
O13	15.30–17.00	**Keeping the Patient in the Centre of Quality Care: What Matters?** — **Clyde Auditorium**
		In collaboration with the International AIDS Society (IAS)
O13CH O13CH		Co-Chairs: *Linda-Gail Bekker* *Anton Pozniak, St Stephen's Centre, Chelsea and Westminster NHS Trust, London, UK, and Governing Council, IAS*
O13CH	15.30–15.35	**Welcome, introduction and setting the scene** *Linda-Gail Bekker*

O131	15.35–15.50	**Confidentiality matters: innovative HIV testing** *Cheryl Johnson, World Health Organization (WHO), Geneva, Switzerland*	
O132	15.50–16.05	**Convenience matters: catalogue STI testing and PrEP** *Patrick S Sullivan, Rollins School of Public Health, Emory University, Atlanta, USA*	
O133	16.05–16.20	**Context matters: one stop medical care from Eastern Europe to downtown London** *Jeffrey V Lazarus, CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain*	
O134	16.20–16.35	**Choice matters: differentiated models of care** *Helen Bygrave, SAMU (Southern Africa Medical Unit), Médecins Sans Frontières (MSF), Cape Town, South Africa*	
O135	16.35–16.40	**Clients matter: listening to the voices of people living with HIV** *Kevin Osborne, HIV Programmes and Advocacy, IAS, Geneva, Switzerland*	
O13CH	16.40–17.00	**Panel discussion and closing remarks** *Led by Anton Pozniak*	
	17.00–17.30	**Coffee**	**Congress Exhibition Hall (Hall 4)**
SS2	17.30–19.00	**Industry Symposium**	**Clyde Auditorium**

Tuesday 25 October

SS3	08.30–10.00	**Industry Symposium**	**Clyde Auditorium**
	10.00–10.30	**Coffee**	**Congress Exhibition Hall (Hall 4)**
O21	10.30–12.15	**Co-morbidities and HIV Management**	**Clyde Auditorium**
O21CH		Co-Chairs: *Lene Ryom, Department of Infectious Diseases and Rheumatology, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark*	
O21CH		*Juan-Sierra Madero, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico*	
O211	10.30–10.50	**Helping the HIV physician through the challenges of co-morbidities** *Edouard Battegay, Center of Competence Multimorbidity, University Hospital Zurich, Zurich, Switzerland*	
O212*	10.50–11.05	**HIV patients today and 10 years ago: do they have the same needs? Results from cross-sectional analysis of ANRS CO3 Aquitaine cohort** *Charles Cazanave, Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France*	

*Please see pages 20–25 for full author details of oral papers.

SCIENTIFIC PROGRAMME (continued)

O213*	11.05–11.20	**Long-term impact of lipodystrophy on the risk of morbidity and mortality: a 20-year longitudinal cohort study** *Esteban Martinez, Infectious Diseases Unit, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain*
O214*	11.20–11.35	**Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients** *Michael Sabranski, Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany*
O215*	11.35–11.50	**Cognitive function and depression in HIV-positive individuals and matched controls** *Davide De Francesco*
	11.50–12.15	**Panel discussion**
	12.15–13.45	**Scientific Posters and Lunch** — **Congress Exhibition Hall (Hall 4)**
CoS1	12.30–13.35	**Apps and New Technologies in the Management of HIV Infection: Community Session** — **Clyde Auditorium**
		In collaboration with the European AIDS Treatment Group (EATG)
CoS1CH CoS1CH		Co-Chairs: *Lisa Power, Potestatis.com, Cardiff, UK* *Alain Volny-Anne, Bangkok, Thailand*
CoS1CH	12.30–12.35	**Welcome and introduction** *Lisa Power and Alain Volny-Anne*
CoS11	12.35–12.45	**New approaches and new technologies to improve access to HIV testing** *Teymur Noori, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden*
CoS12	12.45–12.55	**How can we start HIV treatment very soon after HIV diagnosis? Can technology help?** *Tarandeep Anand, The Thai Red Cross AIDS and Research Center, Bangkok, Thailand*
CoS13	12.55–13.05	**Monitoring HIV infection: use of new technologies and new approaches** *Jennifer Whetham, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK*
CoS14	13.05–13.15	**Use of medical apps and privacy issues: should we be worried about confidentiality?** *François Houÿez, European Organisation for Rare Diseases (EURORDIS), Paris, France*
	13.15–13.35	**Panel discussion and close**
O22	13.45–15.30	**Co-infections and Malignancies** — **Clyde Auditorium**
O22CH		Chair: *Jürgen Rockstroh, HIV Outpatient Clinic, University of Bonn, Bonn, Germany*

*Please see pages 20–25 for full author details of oral papers.

O221	13.45–14.05	**HCV therapies: what have we achieved and remaining challenges?** *Andri Rauch, Bern University Hospital and University of Bern, Bern, Switzerland*
O222	14.05–14.25	**HPV-associated malignancies in HIV** *Deborah Konopnicki, Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium*
O223	14.25–14.45	**Screening for malignancies: what is new?** *Jean-Philippe Spano, University Institute of Oncology (IUC)/University Pierre and Marie CURIE (UPMC)/Pitié-Salpêtrière Hospital, Paris, France*
O224*	14.45–15.00	**Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study** *Leah Shepherd, Research Department of Infection and Population, University College London, London, UK*
	15.00–15.30	**Panel discussion**
O23	15.30–17.00	**Critical Issues in Eastern and Central Europe Including MDR TB and Hepatitis Co-infection** — **Clyde Auditorium**
		In collaboration with the European AIDS Clinical Society (EACS)
O23CH O23CH		Co-Chairs: *Manuel Battegay, Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland* *Cristiana Oprea, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania*
O23CH	15.30–15.35	**Welcome and introduction** *Manuel Battegay*
O231	15.35–15.55	**MDR or XDR TB: a case study from Eastern Europe** *Cristiana Oprea*
O232	15.55–16.20	**Feedback on the highlights of the TB2016 conference in Durban in July 2016** *Jan Fehr, University Hospital of Zurich, Zurich, Switzerland*
O233	16.20–16.40	**Tackling the HCV epidemic in the EECA region: a physician's perspective** *Nikoloz Chkhartishvili, Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia*
O23PL	16.40–17.00	**Moderated panel discussion (TB and HCV co-infection) and closing remarks** Panel members to include the above and joined by: *Justyna Kowalska, Medical University of Warsaw, Warsaw, Poland* *Jürgen Rockstroh*
O23PL O23PL		
	17.00–17.30	**Coffee** — **Congress Exhibition Hall (Hall 4)**
SS4	17.30–19.00	**Industry Symposium** — **Clyde Auditorium**
	19.00–19.45	**Poster Reception** — **Congress Exhibition Hall (Hall 4)**

*Please see pages 20–25 for full author details of oral papers.

SCIENTIFIC PROGRAMME (continued)

Wednesday 26 October

O31	08.30–10.45	**PrEP in High Income Settings**	**Clyde Auditorium**
		In collaboration with the British HIV Association (BHIVA)	
O31CH		Co-Chairs: *Chloe Orkin, Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK, and Chair, BHIVA*	
O31CH		*Simon Collins, HIV i-Base, London, UK*	
O311	08.30–08.50	**Update on the evidence for PrEP effectiveness** *Sheena McCormack, Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK*	
O312	08.50–09.05	**Brief overview of cost-effectiveness of PrEP** *Valentina Cambiano, University College London, London, UK*	
O313	09.05–09.20	**Lessons from implementation in France** *Jean-michel Molina*	
O314*	09.20–09.35	**Utilisation of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the USA by gender (2013–1Q2016)** *Keith Rawlings, Medical Affairs, Gilead Sciences, Foster City, USA (Industry Speaker†)*	
O315*	09.35–09.50	**InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of pharmacokinetics, safety and outcomes** *Nneka Nwokolo, Chelsea and Westminster Hospital, London, UK*	
O316	09.50–10.05	**Implementation strategies across Europe: an overview** *Teymur Noori*	
O317	10.05–10.20	**PrEP implementation from the community perspective** *Bruno Spire, French National Institute for Medical Research (INSERM), and AIDES, Pantin, France*	
	10.20–10.45	**Panel, audience discussion and closing remarks**	
	10.45–11.15	**Coffee**	**Congress Exhibition Hall (Hall 4)**
O32	11.15–12.15	**The Way Forward**	**Clyde Auditorium**
O32CH		Co-Chairs: *Praphan Phanuphak, Thai Red Cross AIDS Research Center, Bangkok, Thailand*	
O32CH		*Ian Weller, University College London, London, UK*	
O321	11.15–11.45	**Immunology of HIV persistence: implications for the development of a cure** *Steven G Deeks, University of California, San Francisco, USA*	
O322	11.45–12.15	**Where next for ARVs?** *Roy M Gulick*	

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.

	12.15–13.30	**Scientific Posters and Lunch**
	12.30–13.10	**Renal and Bone: Poster Discussion Session** **Clyde Auditorium**
PCH		Co-Chairs: *Jose Gatell, Infectious Diseases Unit, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain*
PCH		*Veronica Miller, Forum for Collaborative HIV Research, UC Berkeley School of Public Health, Washington DC, USA*
P218	12.30–12.40	**Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir** *Sophie Jose, Department of Infection and Population Health, University College London, London, UK*
P219	12.40–12.50	**Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV co-infected individuals in sub-Saharan Africa: results from the HEPIK cohort** *Giovanni Villa, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK*
P169	12.50–13.00	**The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort** *Tara McGinty, School of Medicine/HIV Molecular Research Group, University College Dublin, Dublin, Ireland*
P093	13.00–13.10	**Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent** *Frank Post, HIV Research Centre, King's College Hospital, London, UK*
	12.30–13.20	**Pharmacokinetics and Drug Interactions: Poster Discussion Session** **Lomond Auditorium**
PCH		Co-Chairs: *David Cooper, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia*
PCH		*Patrick Mallon, School of Medicine, University College Dublin, Dublin, Ireland*
P031	12.30–12.40	**Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin** *Sandra Soeria-Atmadja, Division of Pediatrics, Karolinska Institutet, CLINTEC, Stockholm, Sweden*
P302	12.40–12.50	**Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants** *Catherine Chappell, Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, USA*

SCIENTIFIC PROGRAMME (continued)

P094	12.50–13.00	**Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch** *Laura Dickinson, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK*
P142	13.00–13.10	**Low rifampicin and isoniazid concentrations are associated with delayed sputum conversion in HIV-positive patients co-infected with tuberculosis in Uganda** *Christine Sekaggya, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda*
P301	13.10–13.20	**Interactions between HIV and HCV therapies: how common and who wins?** *Adele Torkington, North West ID Unit, North Manchester General Hospital, Manchester, UK*
O33	13.30–15.00	**Antiretroviral Strategies and New Drugs** — **Clyde Auditorium**
O33CH O33CH		Co-Chairs: *Sean Emery, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia* *Ian Williams*
O331*	13.30–13.45	**Non-inferiority of dual-therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial** *José Arribas, HIV Unit, Hospital La Paz, IdiPAZ, Madrid, Spain*
O332*	13.45–14.00	**French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network)** *Anne-Genevieve Marcelin, Department of Virology, Pitie-Salpetriere Hospital, Paris, France*
O333*	14.00–14.15	**Switching from cART to dolutegravir (DTG) maintenance monotherapy in virologically suppressed HIV-1-infected adults: a randomised, multicentre, non-inferiority clinical trial (DOMONO)** *Bart Rijnders, Internal Medicine, Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands*
O334*	14.15–14.30	**Subgroup analyses from ONCEMRK, a phase 3 study of raltegravir (RAL) 1200 mg once daily versus RAL 400 mg twice daily, in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects** *Pedro Cahn*
O335A*	14.30–14.45	**HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 subgroup analysis** and **HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 safety analysis** *Cyril Llamoso, Research and Development, ViiV Healthcare, Wallingford, USA (Industry Speaker†)*
O335B*		

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.

O336*	14.45–15.00	**Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomised, controlled, phase 3, non-inferiority TALENT study** *Dong Xie, Research and Development, Frontier Biotechnologies Co, Nanjing, China (Industry Speaker†)*	
	15.00–15.15	**Congress Closing Remarks**	**Clyde Auditorium**
		Giulio Corbelli, European AIDS Treatment Group (EATG), Brussels, Belgium, and Bologna, Italy *Andrew Phillips*	

Biographies and photographs of invited speakers presenting at HIV Glasgow can be found on the Congress app. The Congress app is available for download – instructions on how to download the Congress app are available at the Congress Registration Area.

*Please see pages 20–25 for full author details of oral papers.
†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.

Submitted abstracts accepted for oral presentation within the main programme, including full author group and affiliations

Sunday 23 October

O114 **Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe**

Kamilla Grønborg Laut[1]; Leah Shepherd[2]; Roxana Radoi[3]; Igor Karpov[4]; Milosz Parczewski[5]; Cristina Mussini[6]; Fernando Maltez[7]; Marcelo Losso[8]; Nikoloz Chkhartishvili[9]; Hila Elinav[10]; Helen Kovari[11]; Anders Blaxhult[12]; Robert Zangerle[13]; Tatiana Trofimora[14]; Brygida Knysz[15]; Kai Zilmer[16]; Elena Kuzovatova[17]; Therese Staub[18]; Dorthe Raben[1]; Jens Lundgren[1]; Amanda Mocroft[2]; Ole Kirk[1]

[1]Department of Infectious Diseases, CHIP, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Section 2100, Copenhagen, Denmark; [2]Department of Infection and Population Health, University College London, London, UK; [3] Spitalul de Boli Infectioase si Tropical, Dr Victor Babes Hospital, Bucharest, Romania; [4]Department of Infectious Diseases, Belarus State Medical University, Minsk, Belarus; [5]Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland; [6]Department of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy; [7]Servico de Doencas Infecciosas, Hospital de Curry Cabral, Lisbon, Portugal; [8]Servicio de Immunocomprometidos, Hospital JM Ramos Mejia, Buenos Aires, Argentina; [9]Department of Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia; [10]Department of Clinical Microbiology and Infectious Diseases, Hadassah Hospital, Jerusalem, Israel; [11]Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Zürich, Switzerland; [12]Department of Infectious Diseases, Södersjukhuset, Venhälsan, Stockholm, Sweden; [13]Department of Dermatology and Venerology, Medical University Innsbruck, Innsbruck, Austria; [14]Department of Infectious Diseases, Novgorod Centre for AIDS Prevention and Control, Velikij Novgorod, Russian Federation; [15]Department of Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; [16]Centre of Infectious Diseases, West-Tallin Central Hospital, Tallin, Estonia; [17]Privolzhsky Federal District AIDS Control and Prevention Center, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician IN Blokhina, Nizhny Novgorod, Russian Federation; [18]Service des Maladies Infectieuses, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg

O121 **Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial**

Roberta Gagliardini[1]; Massimiliano Fabbiani[1]; Eugenia Quiros Roldan[2]; Alessandra Latini[3]; Gabriella D'Ettorre[4]; Andrea Antinori[5]; Antonella Castagna[6]; Giancarlo Orofino[7]; Daniela Francisci[8]; Pierangelo Chinello[9]; Giordano Madeddu[10]; Pierfrancesco Grima[11]; Stefano Rusconi[12]; Barbara Del Pin[13]; Annalisa Mondi[1]; Alberto Borghetti[1]; Emanuele Focà[2]; Manuela Colafigli[14]; Roberto Cauda[1]; Simona Di Giambenedetto[1]; Andrea De Luca[15]

[1]Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy; [2]Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; [3]Department of Infectious Dermatology and Allergology, IFO San Gallicano Institute (IRCCS), Rome, Italy; [4]Department of Infectious Diseases, La Sapienza University, Rome, Italy; [5]Department of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy; [6]Department of Infectious and Tropical Diseases, Vita-Salute San Raffaele University, San Raffaele Hospital, Milan, Italy; [7]Infectious and Tropical Diseases Unit, Amedeo di Savoia Hospital, Torino, Italy; [8]Infectious Diseases Clinic, University of Perugia, Perugia, Italy; [9]Systemic Infections and Immunodeficiency Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy; [10]Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy; [11]Division of Infectious Diseases, Santa Caterina Novella Hospital, Galatina, Italy; [12]Infectious Disease Unit, Dipartimento di Scienze Biomediche e Cliniche, Luigi Sacco, University of Milan, Milan, Italy; [13]Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy; [14]Infectious Dermatology and Allergology Unit, IFO San Gallicano Institute (IRCCS), Rome, Italy; [15]Infectious Diseases Unit, Siena University Hospital, Siena, Italy

O122 **Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial**

Laura Ciaffi[1]; Sinata Koulla-Shiro[2]; Adrien Sawadogo[3]; N Fatou Ngom Gueye[4]; Vincent Le Moing[1]; Sabrina Eymard-Duvernay[1]; Suzanne Izard[1]; Jacques Zoungrana[3]; Pretty Mbouyap[5]; Mamadou Diallo[6]; Guillaume Bado[3]; Koumba Toure Kane[7]; Avelin Aghokeng[8]; Martine Peeters[1]; Jacques Reynes[9]; Eric Delaporte[1]

[1]UMI 233, IRD INSERM, Montpellier, France; [2]Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; [3]Hôpital de Jour, Centre Hospitalier Universitaire de Souro Sanou, Bobo Dioulasso, Burkina Faso; [4]Hôpital de Jour, Centre Hospitalier Universitaire de Fann, Dakar, Senegal; [5]Projet MOBIDIP, Agence Nationale de Recherche sur le SIDA et les hépatites virales (Cameroun Site), Yaounde, Cameroon; [6]CRCF, Centre Hospitalier Universitaire de Fann, Dakar, Senegal; [7]Laboratoire de Bactériologie-Virologie, Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Senegal; [8]Centre de Recherche sur les Maladies Emergentes et, Virology Laboratory IMPM-IRD, Yaounde, Cameroon; [9]Maladies Infectieuses, Centre Hospitalier Universitaire Montpellier, Montpellier, France

O123 **Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)**

Nicolas Margot[1]; Renee Ram[1]; Moupali Das[2]; Marshall Fordyce[2]; Scott McCallister[2]; Michael Miller[1]; Christian Callebaut[1]

[1]Department of Clinical Virology, Gilead, Foster City, USA; [2]Department of Clinical Research, Gilead, Foster City, USA

O124 **Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks**

Chloe Orkin[1]; Edwin DeJesus[2]; Moti Ramgopal[3]; Gordon Crofoot[4]; Peter Ruane[5]; Anthony LaMarca[6]; Anthony Mills[7]; Bernard Van der Cam[8]; Joseph De Wet[9]; Jurgen Rockstroh[10]; Adriano Lazzarin[11]; Bart Rijnders[12]; Daniel Podzamczer[13]; Anders Thalme[14]; Marcel Stoeckle[15]; Danielle Porter[16]; Hui Liu[17]; Andrew Cheng[18]; Erin Quirk[18]; Devi SenGupta[18]; Huyen Cao[18]

[1]Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK; [2]Private Practice, Orlando Immunology Center, Orlando, USA; [3]Research Facility, Midway Immunology and Research Center, Fort Pierce, USA; [4]Research Facility, The Crofoot Research Center, Houston, USA; [5]Private Practice, Peter Jerome Ruane, Los Angeles, USA; [6]Research Facility, Therafirst Medical Center, Fort Lauderdale, USA; [7]Private Practice and Research Facility, Mills Clinical Research, Los Angeles, USA; [8]Department of Internal Medicine, Cliniques Universitaires St Luc, Brussels, Belgium; [9]Private Practice, Dr Joseph J de Wet, Vancouver, Canada; [10]Department of Medicine, Bonn University Hospital, Bonn, Germany; [11]Dipartimento di Malettie Infettive, Ospedale San Raffaele, Milan, Italy; [12]Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; [13]AIDS Unit in Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain; [14]Department of Medicine, Division of Infectious Diseases, Karolinska University Hospital, Huddinge, Stockholm, Sweden; [15]Clinic of Infectious Diseases and Hospital Epidemio, University Hospital Basel, Basel, Switzerland; [16]Department of Clinical Virology, Gilead Sciences, Inc, Foster City, USA; [17]Department of Biostatistics – HIV, Gilead Sciences, Inc, Foster City, USA; [18]Department of Clinical Research – HIV, Gilead Sciences, Inc, Foster City, USA

O125 **Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults**

Francois Raffi[1]; Chloe Orkin[2]; Amanda Clarke[3]; Laurence Slama[4]; Joel Gallant[5]; Eric Daar[6]; Mingjin Yan[7]; Michael E Abram[8]; Sandra Friborg[9]; Andrew Cheng[10]; Martin Rhee[10]

[1]Department of Infectious and Tropical Diseases, CHU de Nantes, Nantes, France; [2] Department of Infection and Immunity, Barts Health NHS Trust, London, UK; [3]HIV Unit, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; [4]Department of Infectious and Tropical Diseases, Hôpital Tenon, Paris, France; [5]Specialty Services, Southwest Care Center, Santa Fe, USA; [6]Division of Adult Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, USA; [7]Department of Biostatistics – HIV, Gilead Sciences, Foster City, USA; [8]Department of Clinical Virology, Gilead Sciences, Foster City, USA; [9]Department of Clinical Operations – HIV, Gilead Sciences, Foster City, USA; [10]Department of Clinical Research – HIV, Gilead Sciences, Foster City, USA

O212 **HIV patients today and 10 years ago: do they have the same needs? Results from cross-sectional analysis of ANRS CO3 Aquitaine cohort**

Fabrice Bonnet[1]; Fabien Le Marec[2]; Olivier Leleux[2]; Charles Cazanave[3]; Estibaliz Lazaro[1]; Pierre Duffau[1]; Marie-Anne Vandenhende[1]; Patrick Mercie[1]; Didier Neau[3]; François Dabis[2]

[1]Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; [2]INSERM U1219, Université de Bordeaux, ISPED, Bordeaux, France; [3]Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

O213 **Long-term impact of lipodystrophy on the risk of morbidity and mortality: a 20-year longitudinal cohort study**

Gemma Sanchez; Ana Gonzalez-Cordon; Jhon Rojas; Jose Blanco; Jordi Blanch; Montserrat Lonca; Berta Torres; Maria Martinez-Rebollar; Montserrat Laguno; Amparo Tricas; Ana Rodriguez; Josep Mallolas; Jose Gatell; Judit Peñafiel; Elisa de Lazzari; Esteban Martinez

Infectious Diseases Unit, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

O214 **Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients**

Michael Sabranski[1]; Christoph Wyen[2]; Christian Hoffmann[1]; Tanya Welz[2]; Michael Kolb[2]; Eva Wolf[3]; Hans-Juergen Stellbrink[1]

[1]Department of Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany; [2]Department of Infectious Diseases, Praxis am Ebertplatz, Cologne, Germany; [3] Department of Infectious Diseases, MUC Research, Munich, Germany

O215 **Cognitive function and depression in HIV-positive individuals and matched controls**

Davide De Francesco[1]; Jonathan Underwood[2]; Marta Boffito[3]; Frank Post[4]; Patrick Mallon[5]; Jaime Vera[6]; Ian Williams[1]; Jane Anderson[7]; Margaret Johnson[8]; Caroline Sabin[1]; Alan Winston[2]

[1]Department of Infection and Population Health, University College London, London, UK; [2] Division of Infectious Diseases, Imperial College London, London, UK; [3]Pharmacokinetic Research Unit, Chelsea and Westminster Hospital, London, UK; [4]HIV Research Centre, King's College Hospital, London, UK; [5]School of Medicine, University College Dublin, Dublin, Ireland; [6]Lawson Unit, Brighton and Sussex Medical School, Brighton, UK; [7]Centre for the Study of Sexual Health and HIV, Homerton University Hospital, London, UK; [8]HIV/AIDS Services, Royal Free Hospital, London, UK

O224 **Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study**

Leah Shepherd[1]; Lene Ryom[2]; Matthew Law[3]; Camilla Hatleberg[2]; Stephane de Wit[4]; Antonella d'Arminio Monforte[5]; Manuel Battegay[6]; Andrew Phillips[1]; Fabrice Bonnet[7]; Peter Reiss[8]; Christian Pradier[9]; Andrew Grulich[3]; Caroline Sabin[1]; Jens Lundgren[2]; Amanda Mocroft[1]

[1]Department of Infection and Population Health, University College London, London, UK; [2]Department of Infectious Diseases, Section 2100, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; [3]The Kirby Institute, University of New South Wales, Sydney, Australia; [4]Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium; [5]Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy; [6]Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; [7]CHU de Bordeaux and INSERM U897, Université de Bordeaux, Talence, France; [8]Division of Infectious Diseases, Academic Medical Centre, University of Amsterdam, and Department of Global Health, HIV Monitoring Foundation, Amsterdam, The Netherlands; [9]Department of Public Health, Nice University Hospital, Nice, France

O314 **Utilisation of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the USA by gender (2013–1Q2016)**

Staci Bush[1]; Keith Rawlings[1]; David Magnuson[2]; Patty Martin[1]; Olga Lugo-Torres[1]; Robertino Mera-Giler[3]

[1]Department of Medical Affairs, Gilead Sciences, Foster City, USA; [2]Drug Safety and Public Health, Gilead Sciences, Foster City, USA; [3]Department of Epidemiology, Gilead Sciences, Foster City, USA

O315 **InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of pharmacokinetics, safety and outcomes**

Xinzhu Wang[1]; Nneka Nwokolo[2]; Roxanna Korologou-Linden[1]; Andrew Hill[3]; Gary Whitlock[2]; Isaac Day-Weber[1]; Myra McClure[1]; Marta Boffito[3]

[1]Faculty of Medicine, Imperial College London, London, UK; [2]Chelsea and Westminster Hospital, London, UK; [3]St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK

O331 **Non-inferiority of dual-therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial**

Federico Pulido[1]; Esteban Ribera[2]; Maria Lagarde[1]; Ignacio Pérez-Valero[3]; Jesús Santos[4]; José Iribarren[5]; Antonio Payeras[6]; Pere Domingo[7]; José Sanz[8]; Miguel Cervero[9]; Adrian Curran[2]; Francisco Rodriguez[10]; María Téllez[11]; Pablo Ryan[12]; Pilar Barrufet[13]; Hernando Knobel[14]; Antonio Rivero[15]; Belén Alejos[16]; María Yllescas[16]; José Arribas[3]; Study Group GESIDA-8014-DUAL[17]

[1]HIV Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; [2]Servicio de Enfermedades Infecciosas, Hospital Vall d'Hebron, Barcelona, Spain; [3]HIV Unit, Hospital La Paz, IdiPAZ, Madrid, Spain; [4]Unidad de Enfermedades Infecciosas, Hospital Virgen de la Victoria, Málaga, Spain; [5]Servicio de Enfermedades Infecciosas, Hospital Donostia, San Sebastián, Spain; [6]Servicio de Medicina Interna, Hospital Son Llatzer, Palma de Mallorca, Spain; [7]Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; [8]Servicio de Medicina Interna, Hospital Príncipe de Asturias, Alcalá de Henares, Spain; [9]Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Spain; [10]Unidad de Enfermedades Infecciosas, Hospital Infanta Elena, Huelva, Spain; [11]Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, Spain; [12]Servicio de Medicina Interna, Hospital Infanta Leonor, Madrid, Spain; [13]Servicio de Medicina Interna, Hospital de Mataró, Mataró, Spain; [14]Servicio de Enfermedades Infecciosas, Hospital del Mar, Barcelona, Spain; [15]Sección de Enfermedades Infecciosas, Hospital Reina Sofia, Córdoba, Spain; [16]Fundación de Investigación, SEIMC-GESIDA, Madrid, Spain; [17]GESIDA-8014-DUAL Study Group, Spain

O332 **French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network)**

Anne-Genevieve Marcelin[1]; Maxime Grude[2]; Charlotte Charpentier[3]; Pantxika Bellcave[4]; Audrey Rodallec[5]; Coralie Pallier[6]; Stephanie Raymond[7]; Audrey Mirand[8]; Laurence Bocket[9]; Laurence Morand-Joubert[10]; Constance Delaugerre[11]; Brigitte Montes[12]; Helene Jeulin[13]; Thomas Mourez[14]; Samira Fafi-Kremer[15]; Corrine Amiel[16]; Catherine Roussel[17]; Julia Dina[18]; Marie-Anne Trabaud[19]; Helene Le Guillou-Guillemette[20]; Sophie Valet[21]; Anne Signori-Schmuck[22]; Anne Maillard[23]; Anne Krivine[24]; Philippe Flandre[2]; Diane Descamps[3]; Vincent Calvez[1]

[1]Department of Virology, Pitie-Salpetriere Hospital, Paris, France; [2]Inserm U1136, Pitie-Salpêtriere Hospital, Paris, France; [3]Department of Virology, Bichat Hospital, Paris, France; [4]Department of Virology, Bordeaux Hospital, Bordeaux, France; [5]Department of Virology, Nantes Hospital, Nantes, France; [6]Department of Virology, Paul Brousse Hospital, Paris, France; [7]Department of Virology, Toulouse Hospital, Paris, France; [8]Department of Virology, Clermont-Ferrand Hospital, Clermond-Ferrand, France; [9]Department of Virology, Lille Hospital, Lille, France; [10]Department of Virology, Saint Antoine, Paris, France; [11]Department of Virology, Saint Louis Hospital, Paris, France; [12]Department of Virology, Montpellier Hospital, Paris, France; [13]Department of Virology, Nancy Hospital, Nancy, France; [14]Department of Virology, Rouen Hospital, Rouen, France; [15]Department of Virology, Strasbourg Hospital, Strasbourg, France; [16]Department of Virology, Tenon Hospital, Paris, France; [17]Department of Virology, Amiens Hospital, Amiens, France; [18]Department of Virology, Caen Hospital, Caen, France; [19]Department of Virology, Lyon Hospital, Lyon, France; [20]Department of Virology, Angers Hospital, Angers, France; [21]Department of Virology, Brest Hospital, Brest, France; [22]Department of Virology, Grenoble Hospital, Grenoble, France; [23]Department of Virology, Rennes Hospital, Rennes, France; [24]Department of Virology, Cochin Hospital, Paris, France

O333 **Switching from cART to dolutegravir (DTG) maintenance monotherapy in virologically suppressed HIV-1-infected adults: a randomised, multicentre, non-inferiority clinical trial (DOMONO)**

Ingeborg Wijting[1]; Casper Rokx[1]; Charles Boucher[2]; Jeroen Van Kampen[2]; Dorine De Vries-Sluijs[1]; Karin Schurink[1]; Hannelore Bax[1]; Maarten Derksen[1]; Elrozy Andrinopoulou[3]; Ineke Van der Ende[1]; Eric Van Gorp[1]; Jan Nouwen[1]; Annelies Verbon[1]; Wouter Bierman[4]; Bart Rijnders[1]

[1]Department of Internal Medicine, Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands; [2]Department of Virology, Erasmus MC, Rotterdam, The Netherlands; [3]Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands; [4]Department of Internal Medicine, Infectious Diseases, Universitair Medisch Centrum Groningen, Groningen, The Netherlands

O334 **Subgroup analyses from ONCEMRK, a phase 3 study of raltegravir (RAL) 1200 mg once daily versus RAL 400 mg twice daily, in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects**

Pedro Cahn[1]; Richard Kaplan[2]; Paul Sax[3]; Kathleen Squires[4]; Jean-michel Molina[5]; Anchalee Avihingsanon[6]; Winai Ratanasuwan[7]; Evelyn Rojas[8]; Mohammed Rassool[9]; Xia Xu[10]; Anthony Rodgers[10]; Sandy Rawlins[10]; Bach-Yen Nguyen[10]; Randi Leavitt[10]; Hedy Teppler[10]

[1]Juan A Fernandez Hospital, Fundacion Huesped, Buenos Aires, Argentina; [2]Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa; [3]Brigham and Women's Hospital, Harvard Medical School, Boston, USA; [4]Department of Infectious Diseases, Thomas Jefferson University, Philadelphia, USA; [5]Hopital Saint-Louis, University of Paris Diderot, Paris, France; [6]Medical Department, HIV-NAT Research Collaboration, Bangkok, Thailand; [7]Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; [8]Department of Infectious Diseases, Cericap Multiclinicas, Guatemala City, Guatemala; [9]Helen Joseph Hospital, University of Witwatersrand, Johannesburg, South Africa; [10]Department of Research, Merck & Co, Inc, Kenilworth, USA

O335A **HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 subgroup analysis**

Enrique Rafael Granados-Reyes[1]; Louis Sloan[2]; Jerome Ernst[3]; Mey León[4]; David Stock[5]; Cyril Llamoso[6]; Samit Joshi[5]; George Hanna[7]; Max Lataillade[6]

[1]Centro de Investigación Clinica Gramel SC, Mexico City, Mexico; [2]Research Department, North Texas Infectious Diseases Consultants, Dallas, USA; [3]AIDS Community Research Initiative of America, New York, USA; [4]Department of Infectious and Tropical Diseases, Asociacion Civil Impacta Salud y Educacion, Lima, Peru; [5]Department of Research and Development, Bristol-Myers Squibb, Wallingford, USA; [6]Department of Research and Development, ViiV Healthcare, Wallingford, USA; [7]Department of Research and Development, Bristol-Myers Squibb, Princeton, USA

O335B **HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 safety analysis**

Cyril Llamoso[1]; Johannes Bogner[2]; Larissa Afonina[3]; Mey León[4]; Alexey Yakovlev[5]; David Stock[6]; Samit Joshi[6]; George Hanna[7]; Max Lataillade[1]

[1]Department of Research and Development, ViiV Healthcare, Wallingford, USA; [2]Section for Infectious Diseases, Hospital of the University of Munich, Med IV, Munich, Germany; [3]Clinical Research and Medical Information, Republic Hospital of Infectious Diseases, St Petersburg, Russian Federation; [4]Department of Infectious and Tropical Diseases, Asociacion Civil Impacta Salud y Educacion, Lima, Peru; [5]Department of Infectious Diseases, St Petersburg Botkin Clinical Infectious Diseases Hospital, St Petersburg, Russian Federation; [6]Department of Research and Development, Bristol-Myers Squibb, Wallingford, USA; [7]Department of Research and Development, Bristol-Myers Squibb, Princeton, USA

O336 **Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomised, controlled, phase 3, non-inferiority TALENT study**

Hao Wu[1]; Cheng Yao[2]; Tong Zhang[1]; Qingxia Zhao[3]; Weiping Cai[4]; Min Wang[5]; Hongzhou Lu[6]; Hui Wang[7]; Yuhuang Zheng[8]; Biao Zhu[9]; Jianhua Yu[10]; Yongtao Sun[11]; Min Zhao[12]; Wenhui Lun[13]; Wei Xia[1]; Qingshan Zheng[14]; Haiyan Peng[15]; Rongjian Lu[16]; Jianhua Hu[2]; Hui Xing[17]; Yiming Shao[17]; Meixia Wang[18]; Dong Xie[19]

[1]Department of Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing, China; [2]Department of Clinical Development, Frontier Biotechnologies Co, Nanjing, China; [3]Department of AIDS Control, Infectious Disease Hospital of Henan Province, Zhengzhou, China; [4]Department of Infectious Diseases, The Eighth People's Hospital of Guangzhou, Guangzhou, China; [5]Department of AIDS Control, The First Hospital of Changsha, Changsha, China; [6]Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai, China; [7]Department of AIDS Control, The Third People's Hospital of Shenzhen, Shenzhen, China; [8]Department of AIDS Control, The Second Xiangya Hospital of Central South University, Changsha, China; [9]Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, China; [10]Department of AIDS Control, Xixi Hospital of Hangzhou, Hangzhou, China; [11]Department of Infectious Diseases, Tangdu Hospital of The Fourth Military Medical University, Xian, China; [12]Department of AIDS Control, 302 Military Hospital of China, Beijing, China; [13]Department of AIDS Control, Beijing Ditan Hospital, Capital Medical University, Beijing, China; [14]Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Biostatistics, Shanghai, China; [15]Department of Clinical Operations, Beijing Co-CRO Medical Development Co, Ltd, Beijing, China; [16]Department of Research and Development, Frontier Biotechnologies Co, Nanjing, China; [17]Department of Virology, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; [18]Department of Clinical Research, Beijing You'an Hospital, Capital Medical University, Beijing, China; [19]Department of Research and Development, Frontier Biotechnologies Co, Nanjing, China